Gene editing stocks are skyrocketing.
While it’s not clear why, it may be thanks in part to Ark Investment Management CEO Cathie Wood, who noted, “I would have to say the biggest upside surprises are going to come from the genomic space. That’s because the convergence of DNA editing, artificial intelligence, and gene therapies, importantly CRISPR gene editing, is going to cure disease,” as quoted by The Motley Fool.
At the moment, Editas Medicine (EDIT) is up 46% to $94. In addition to the comments from Wood, the company recently filed a request with the US FDA to begin a Phase 1/2 study of EDIT-301 for sickle cell disease, which could be a winner given the success of preclinical data.
“This IND submission is a key milestone for Editas as we continue to advance several ex vivo cell therapy medicines. This submission brings us one step closer to entering the clinic with our potentially best-in-class, transformative, and durable medicine for people living with sickle cell disease,” said Cynthia Collins, Chief Executive Officer, Editas Medicine. “This moment is very exciting for the Editas team. We know patients are counting on us, and we look forward to next steps for the clinical development of EDIT-301, including dosing sickle cell disease patients.”
The company’s EDIT-101 for Leber congenital amaurosis type 10 – a leading cause of childhood blindness—could be a game-changer, too.
Other gene editing stocks are exploding alongside EDIT, including Intellia Therapeutics (NLTA), up 21% to $67.01, and CRISPR Therapeutics (CRSP), up 15% to $171.10.